Camlin Fine Sciences Q4 FY26: Paying 81x Earnings for a 1% ROE?

1. At a Glance

Camlin Fine Sciences (CFS) closed FY26 with a consolidated revenue of ₹1,723 Cr, eking out a modest 3.4% YoY growth. The headline net profit figure of ₹27.63 Cr suggests a massive turnaround from the ₹139 Cr loss in FY25, but the surface calm hides a turbulent core. The current market price of ₹117 masks a deeply complicated operational reality where the reported numbers have been heavily cosmetized by the liquidation of the European subsidiary. Turnarounds are often priced for perfection, but executed in chaos.

A closer look reveals that the “profit” is primarily a one-off accounting gain (~₹100 Cr) from loss of control in their discontinued European operations. Continuing operations are still bleeding. Management is actively pivoting away from commoditized performance chemicals toward higher-margin blends and aroma ingredients, but elevated freight costs and stretched working capital are putting serious stress on execution. For investors, the immediate question isn’t whether the pivot is smart—it’s whether the balance sheet can endure the transition while the market prices the stock at over 80 times trailing earnings.

Let’s dissect the wreckage and the rescue plan.

2. Introduction

CFS is a global player in specialty chemicals, primarily known for shelf-life solutions (antioxidants) and aroma ingredients. Over the past few years, the company has been trying to climb the value chain, shifting away from basic chemical “straights” to custom blends and forward-integrated products. Recently, they’ve been cleaning house—shutting down structurally unviable plants in Europe and acquiring a majority stake in Vinpai to boost their natural and plant-based functional ingredients portfolio. The strategy makes sense on paper; the execution on the ground is where things get spicy.

3. Business Model: WTF Do They Even Do?

If you’ve ever wondered why your dog’s kibble doesn’t go rancid after sitting in a warehouse for six months, you can probably thank CFS. They are a market leader in antioxidants like TBHQ and BHA, which literally stop things from spoiling.

Their business is split across:

• Shelf-Life Solutions (72%): The core engine. Divided into “Straights” (basic antioxidants where pricing is a knife-fight) and “Blends” (custom formulations where margins theoretically live).
• Performance Chemicals (26%): Downstream derivatives. This segment is currently undergoing a strategic starvation diet because making the inputs in-house became costlier than just buying them from China.
• Aroma Ingredients (2%): They make Vanillin. Yes, the fake vanilla flavor in your ice cream.

4. Financials Overview

Figures are consolidated, in ₹ crore.

Note: Q4 PAT is heavily distorted by an ~₹85-95 Cr gain from discontinued operations.

The revenue line is flatlining, and the core operational EBITDA of ₹21.19 Cr in Q4 is a shadow of its former self. When management starts talking about “discontinued operations” saving the quarter, earnings quality is usually the first casualty. Management relies heavily on “Adjusted EBITDA”—the corporate equivalent of saying, “I would have won the marathon if I didn’t have to actually run it.”

What is Management Promising in the Coming Quarters?

The Q4 concall was a mix of swagger and supply-chain PTSD. Management pointed to the Red Sea crisis as a major drag, noting that executing their growth plan “with tight cash flow… is a bigger challenge than the market itself.” However, they remain fiercely optimistic about passing on inflation in the Straights business, declaring, “we will be able to pass on and we are passing on.” They’ve also halted their cash-burning diphenols production, opting to just import raw materials. For FY27, they are promising a revenue of ₹2,200–2,400 Cr with 12-14% margins. Givens are usually written down somewhere.